Angiotensin neprilysin inhibition in HFpEF and advanced left ventricular hypertrophy: the rationale, design, and preliminary results of a randomized open-label pilot study

29 June 2021 (08:00 - 23:59)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Anna Gvozdeva

National Medical Research Center for Cardiology, Moscow (Russian Federation)

738 More presentations in this session

Presentation thumbnail

Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?

Assistant Professor N. Radovanovic (Belgrade, RS)

Abstract Slides

Presentation thumbnail

Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF

Assistant Professor V. Kirillova (Ekaterinburg, RU)

Abstract Slides

Presentation thumbnail

Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum

Doctor D. Moysidis (Zurich, CH)

Abstract Slides

Presentation thumbnail

Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation

Doctor A. Safiullina (Moscow, RU)

Abstract Slides

Presentation thumbnail

Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?

Doctor H. Santos (Lisboa, PT)

Abstract Slides

Access the full session

Session thumbnail

ePoster session

The Event

Heart Failure 2021

29 June 2021 08:00 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Session

Acute heart failure therapies: from clinical trials to clinical practice

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023